Anti‐CD3 mAbs for treatment of type 1 diabetes

@article{Kaufman2009AntiCD3MF,
  title={Anti‐CD3 mAbs for treatment of type 1 diabetes},
  author={Adam H. Kaufman and Kevan C. Herold},
  journal={Diabetes/Metabolism Research and Reviews},
  year={2009},
  volume={25}
}
  • A. Kaufman, K. Herold
  • Published 1 May 2009
  • Biology, Medicine
  • Diabetes/Metabolism Research and Reviews
The use of anti‐CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti‐human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non‐FcR binding antibodies: Teplizumab, Otelixizumab and Visilizumab. Preclinical studies showed the ability of the drugs to reverse hyperglycaemia in diabetic non‐obese diabetic (NOD) mice providing rationale for clinical trials with the… 
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus
TLDR
Otelixizumab is a drug of potential interest for treating new onset T1DM patients and its use in combination with other immunomodulatory agents should be considered as a solution to circumvent adverse effects while maintaining efficacy.
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
TLDR
The current knowledge of the immunopathogenesis of type 1 diabetes and how this information has been translated into clinical trials is discussed and next-generation combination immunotherapies that may be administered as adjuvant therapy at time of diagnosis are discussed.
Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment
TLDR
A new humanized mouse model that expresses the human isoform of a molecule targeted by T1D antibody therapies that are currently being tested in clinical trials—the human epsilon chain of the CD3 complex expressed on T cells is described.
Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
TLDR
This review will discuss the status of various T1D therapeutic strategies tested in the clinic, as well as possible combinatorial approaches to restore β cell tolerance.
Effects of anti‐CD3 monoclonal antibody in salivary glands of spontaneously diabetic mice
TLDR
Results indicate that immunotherapy contributed to reestablishment of tissue damaged by the hyperglycemic condition, demonstrating that the immunomodulation plays an important role in the recovery of salivary glands.
Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody
TLDR
The establishment of other Abs that recognize CD3ε, even though the determinant recognized by those Abs may be close to or different from that recognized by OKT3, may represent a novel approach for the development of safer Ab therapies using anti-CD3 Abs, in addition to the modification ofOKT3 in terms of the induction of cytokine production.
Immunotherapy for Type 1 Diabetes – Preclinical and Clinical Trials
TLDR
Type 1 diabetes is an organ-specific autoimmune disease resulting from the selective destruction of pancreatic insulin secreting beta cells by autoreactive CD4 and CD8 effector T lymphocytes which normally play an important role in self-protection by killing infected and tumor cells.
Novel CD3‐specific antibody induces immunosuppression via impaired phosphorylation of LAT and PLCγ1 following T‐cell stimulation
TLDR
A novel monoclonal antibody, Dow2, is established that temporarily induces downmodulation of the TCR/CD3 complex in mouse CD4+ T cells without activating T cells and may provide us with a unique tool for inducing immunosuppression.
Immunological profile and aspects of immunotherapy in type 1 diabetes
TLDR
Treatment with GAD-alum in type 1 diabetic children induced an early T-helper 2 immune enhanced response to GAD(65), followed by a wider spectrum of cytokines at 3 and 9 months, which indicated immunomodulation.
Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia
TLDR
MoAbs exhibit a completely different mechanism of anti-leukemic action compared to conventional chemotherapy and certainly will change substantially the design of treatment strategies for childhood ALL in future.
...
...

References

SHOWING 1-10 OF 61 REFERENCES
Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal Antibody
TLDR
It is concluded that treatment with either whole anti-CD3 MoAb or F(ab′)2 fragments suppresses the hyperglycemia and insulitis of MDSDM and may be a useful form of immunosuppressive treatment for incipient IDDM.
The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties
TLDR
The aglycosyl γl CD3 mAb is a promising candidate for immunosuppressive therapy without “first dose” side effects and removal of the carbohydrate moiety from theγl constant region reduced the in vivo tumor necrosis factor‐a response by a factor of at least 16‐fold.
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
TLDR
Data indicate that huOKT3gamma1(ala-ala) may be useful in treating PsA, and indicates that the need for longterm global immunosuppression in autoimmune diseases may be eliminated.
A NON‐ACTIVATING “HUMANIZED” ANTI‐CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO
TLDR
An experimental model in which human splenocytes from cadaveric organ donors were inoculated into severe combined immunodeficient mice to test the activating and immunosuppressive properties of these anti-human CD3 mAbs in vivo suggests the use of an Fc variant in clinical transplantation should result in fewer side effects than observed with OKT3, while maintaining its clinical efficacy.
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.
TLDR
Findings suggest that CD3 antibodies can be engineered to lose their toxicity while retaining their potency as immunosuppressants in the management of transplant patients and in therapy of autoimmune diseases.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
TLDR
A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy and pharmacokinetics, safety, and immunosuppressive activity of visilizumab in GVHD.
A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes
TLDR
It is concluded that treatment with the anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improved C-peptide responses and clinical parameters in type 1 diabetes for at least 2 years in the absence of continued immunosuppressive medications.
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
TLDR
Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes, as suggested by the results of a phase 1 study.
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
TLDR
It is demonstrated that a novel combination treatment with anti-CD3epsilon-specific antibody and i.n. proinsulin peptide can reverse recent-onset diabetes in 2 murine diabetes models with much higher efficacy than with monotherapy with anti -CD3 or antigen alone.
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
TLDR
It is strongly suggested that self-tolerance can be restored in adult mice once autoimmunity is fully established and confirmed that this effect can be obtained by transient targeting of the CD3/T-cell receptor without massive T-cell debulking.
...
...